NOVARTIND.BO Novartis India BSE -17.35% INR 830.45 Pre-Mkt Feb 2026: outlook
The NOVARTIND.BO stock opened the pre-market session on 25 Feb 2026 under heavy selling, trading at INR 830.45, down 17.35% from a previous close of INR 1004.80. The move shows sharp profit-taking after a YTD gain of 21.44% and follows clear technical overbought signals. We break down price drivers, valuation and a short-term outlook for Novartis India Limited (BSE), and flag key support and resistance levels to watch before the market opens.
NOVARTIND.BO stock: Price action and session context
NOVARTIND.BO stock fell to INR 830.45 in pre-market trade on 25 Feb 2026, a drop of 17.35% on low intraday volume of 9,854 shares. The stock traded in a session range between INR 825.00 and INR 858.90, after opening at INR 845.35. This single-day gap re-priced expectations and pushed the share back toward its 50-day average of INR 799.27.
Technical drivers: overbought indicators and momentum shift
Technical indicators signalled exhaustion before the fall: RSI at 78.05 and MFI at 98.17 showed overbought conditions. MACD turned less bullish with a histogram gap of 18.49 but the ADX at 28.75 confirms a strong trend. The price is now sitting below the Bollinger middle band (INR 829.54), opening room for short-term consolidation.
Fundamentals and valuation snapshot for Novartis India (BSE)
Novartis India Limited (NOVARTIND.BO) carries a trailing EPS of INR 39.36 and a PE of 24.03, with a PB ratio near 3.20. Market capitalisation stands around INR 23.35B and dividend per share is INR 25.00, implying a yield of about 2.49%. These metrics keep the company in-line with healthcare peers on profitability but above sector average valuation multiples.
Meyka AI grade, forecast and model view
Meyka AI rates NOVARTIND.BO with a score out of 100: 74.20, Grade B+, Suggestion: BUY. This grade factors S&P 500 and sector comparisons, financial growth, key metrics and analyst consensus. Meyka AI’s forecast model projects a yearly target of INR 929.31, a 3-month target of INR 702.62, and a monthly level near INR 783.27. Forecasts are model-based projections and not guarantees.
Key support, resistance and trading levels
Immediate support sits near the day low of INR 825.00 and the 50-day average at INR 799.27. Stronger support is at the 52-week low of INR 744.95. On the upside, resistance appears at INR 858.90 and the 200-day average at INR 895.45. Traders should watch relative volume, which is currently 1.46x the average, for conviction before initiating new positions.
Sector context, risks and catalysts for the healthcare stock
The healthcare sector in India trades at an average PE of 40.59, higher than Novartis India’s PE, which may limit upside if sector flows reverse. Key risks include pricing pressure, channel stocking swings and parent-company licensing changes. Possible catalysts are the next earnings announcement on 07 May 2026, and any INR-denominated product approvals or pricing updates from Novartis AG.
Final Thoughts
NOVARTIND.BO stock’s pre-market decline to INR 830.45 on 25 Feb 2026 reflects a rapid technical unwind after overbought momentum. Fundamentals remain solid with EPS INR 39.36, PE 24.03 and a dividend yield near 2.49%, but the price is testing short-term support near INR 825.00. Meyka AI’s forecast model projects a yearly level of INR 929.31, implying an upside of 11.91% from the current price; conversely the 3-month forecast of INR 702.62 implies a downside of 15.39%. Forecasts are model-based projections and not guarantees. For active traders, watch volume confirmation and a reclaim of INR 858.90 before adding risk. Long-term investors should weigh valuation against sector peers and upcoming earnings on 07 May 2026, and consider position sizing for volatility.
FAQs
Why did NOVARTIND.BO stock fall sharply pre-market on 25 Feb 2026?
The drop was driven by technical profit-taking after overbought signals (RSI 78.05) and high MFI. Low headline volume and a gap down from INR 1004.80 to INR 830.45 amplified selling; no confirmed company-specific negative news was released at the time.
What are the immediate support and resistance levels for NOVARTIND.BO stock?
Immediate support is near INR 825.00 and the 50-day average INR 799.27. Resistance sits at INR 858.90 and the 200-day average INR 895.45. Watch relative volume to confirm breakouts or breakdowns.
How does Meyka AI view Novartis India’s near-term outlook?
Meyka AI rates NOVARTIND.BO 74.20 (B+, BUY) and projects a yearly target of INR 929.31, implying 11.91% upside from current levels. The model also flags a 3-month level at INR 702.62, so risk management is essential.
Which financial metrics should investors check for NOVARTIND.BO stock?
Key metrics include trailing EPS INR 39.36, PE 24.03, PB 3.20, dividend per share INR 25.00, and current ratio measures. Compare these to healthcare peers before making allocation decisions.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.